Table 4 Univariate analysis of disease-free survival rate according to clinicopathological findings and proteins expressions
| Â | Â | Probability of accumulated disease-free survival | Â | ||
|---|---|---|---|---|---|
Variable | Category | 1Â year | 3Â year | 5Â years | p* (log rank) |
| Â | Â | (%) | (%) | (%) | Â |
Gender | Male | 72.2 | 54.8 | 54.8 | 0.736 |
Female | 72.2 | 60.8 | 55.3 | ||
Age | 30–59 years | 71.9 | 53.4 | 53.4 | 0.910 |
60–69 years | 76.8 | 58.5 | 58.5 | ||
70–91 years | 67.4 | 61.7 | 49.4 | ||
Tumor histological grade | SCC I | 82.0 | 63.2 | 60.6 | 0.001 |
SCC II e III | 39.0 | 3.2 | 34.2 | ||
Clinical Stage | IÂ +Â II | 70.4 | 70.4 | 70.4 | 0.457 |
IIIÂ +Â IV | 72.5 | 53.6 | 51.0 | ||
PI3K | Negative | 83.3 | 83.3 | 83.3 | 0.157 |
Positive | 70.1 | 56.0 | 53.7 | ||
p-mTOR cytoplasm | Negative | 77.4 | 58.0 | 58.0 | 0.893 |
Positive | 70.5 | 57.4 | 54.9 | ||
p-mTOR membrane | Negative | 75.2 | 55.5 | 51.5 | 0.745 |
Positive | 67.3 | 60.7 | 60.7 | ||
p-mTOR nuclei | Negative | 68.5 | 50.1 | 47.0 | 0.037 |
Positive | 75.0 | 70.3 | 70.3 | ||
p-MAPK cytoplasm | Negative | 92.9 | 66.5 | 66.5 | 0.360 |
Positive | 68.1 | 56.3 | 53.9 | ||
p-MAPK nuclei | Negative | 73.6 | 60.6 | 53.9 | 0.837 |
Positive | 70.7 | 55.8 | 55.8 | ||
p-AKT cytoplasm | Negative | 85.7 | 68.6 | 68.6 | 0.568 |
Positive | 70.6 | 56.7 | 54.5 | ||
p-AKT nuclei | Negative | 67.9 | 59.9 | 59.9 | 0.923 |
Positive | 74.4 | 56.8 | 53.8 | ||
PTEN cytoplasm | Negative | 84.9 | 74.3 | 66.0 | 0.152 |
Positive | 66.6 | 51.0 | 51.0 | ||
PTEN nuclei | Negative | 84.4 | 70.3 | 62.5 | 0.228 |
Positive | 66.6 | 51.0 | 51.0 | ||
TOTAL | Â | 72.3 | 57.0 | 54.9 | Â |